Last reviewed · How we verify
milbemycin oxime
Milbemycin oxime is a small molecule medication originally developed by Janssen Pharmaceutica, currently owned by Eli Lilly and Company. It is used to treat various parasitic infections in animals, including heartworms and fleas. The commercial status of milbemycin oxime is patented, but it is available under various brand names. Key safety considerations include potential side effects such as vomiting and diarrhea. Milbemycin oxime is not approved for human use.
At a glance
| Generic name | milbemycin oxime |
|---|---|
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
- Vomiting
- Pruritus
- Lethargy
- Diarrhea
- Dermatitis
- Skin Reddening
- Decreased appetite
- Pinnal Reddening
Serious adverse events
- Seizure
- Trembling/twitching
- Salivation/drooling
- Ataxia
- Mydriasis
- Blindness
- Disorientation
Key clinical trials
- Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire (NA)
- Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets (NA)
- Efficacy of Two Dual Active Ingredient Long Lasting Insecticidal Nets for Control of Malaria Transmitted by Pyrethroid Resistant Vectors in Benin (NA)
- INTERCEPTOR Project: From MCI to Dementia
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Mozambique
- Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- milbemycin oxime CI brief — competitive landscape report
- milbemycin oxime updates RSS · CI watch RSS
- portfolio CI